Acute Transient Encephalopathy after Moderna COVID-19 Vaccine

Michela Rosso1, Yaacov Anziska1, Steven R Levine1

  • 1Department of Neurology, SUNY Downstate Health Sciences University, New York, New York, USA.

Insights

A prior COVID-19 infection may increase the risk of transient encephalopathy after mRNA vaccination. This rare neuro-inflammatory reaction resolved without lasting effects in one patient.

Area of Science:

  • Neurology
  • Immunology
  • Vaccinology

Background:

  • Previous coronavirus disease 2019 (COVID-19) infection is known to elicit robust immune responses to mRNA vaccines.
  • The safety and reactogenicity of mRNA vaccines in individuals with prior COVID-19 infection require further investigation.

Observation:

  • A 69-year-old woman with a history of COVID-19 infection developed acute transient encephalopathy within 24 hours of her first Moderna COVID-19 vaccine dose.
  • Symptoms included inattention, disorientation, confusion, weakness, and gait instability, with electroencephalography showing diffuse slowing and triphasic waves.
  • Laboratory tests revealed elevated inflammatory markers and positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) IgG antibodies.

Findings:

  • The patient's neurological symptoms resolved completely within 5 days post-vaccination, with no residual deficits.
  • The event was characterized as a transient inflammatory encephalopathy, likely due to an abnormal immunologic reaction to the vaccine in the context of prior SARS-CoV-2 infection and comorbidities.

Implications:

  • Healthcare providers should be aware of potential neuro-inflammatory reactions following mRNA vaccination in individuals with prior COVID-19 infection.
  • Monitoring for post-vaccination reactogenicity, including neurological symptoms, is crucial in this patient population.
  • This case highlights the complex interplay between prior infection, vaccination, and immune responses, emphasizing the need for vigilance regarding vaccine side effects.